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Abstract
Background: Naturally acquired immunity to clinical malaria is thought to be mainly antibody-mediated, but
reports on antigen targets are contradictory. Recognition of multiple antigens may be crucial for protection. In this
study, the magnitude of antibody responses and their temporal stability was assessed for a panel of malaria
antigens in relation to protection against clinical Plasmodium falciparum malaria.
Methods: Malian children aged two to 14 years were enrolled in a longitudinal study and followed up by passive
and active case detection for seven months. Plasma was collected at enrolment and at the beginning, in the
middle and after the end of the transmission season. Antibody titres to the P. falciparum-antigens apical membrane
protein (AMA)-1, merozoite surface protein (MSP)-119, MSP-3, glutamine-rich protein (GLURP-R0) and circumsporozoite
antigen (CSP) were assessed by enzyme-linked immunosorbent assay (ELISA) for 99 children with plasma available at all
time points. Parasite carriage was determined by microscopy and nested PCR.
Results: Antibody titres to all antigens, except MSP-119, and the number of antigens recognized increased with age.
After malaria exposure, antibody titres increased in children that had low titres at baseline, but decreased in those with
high baseline responses. No significant differences were found between antibody titers for individual antigens between
children remaining symptomatic or asymptomatic after exposure, after adjustment for age. Instead, children remaining
asymptomatic following parasite exposure had a broader repertoire of antigen recognition.
Conclusions: The present study provides immune-epidemiological evidence from a limited cohort of Malian children
that strong recognition of multiple antigens, rather than antibody titres for individual antigens, is associated with
protection from clinical malaria.
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Background
Despite the success of major public health control efforts
in recent years [1], malaria remains one of the most im-
portant causes of morbidity and mortality in the world
with an estimated 207 million cases and 627,000 deaths in
2012 [2]. Antibody-mediated immune responses to mal-
aria antigens help to control blood-stage parasitaemia and
have a protective effect on clinical disease, as shown
in passive transfer experiments [3,4]. Identification of
antigens that are the target(s) of these protective anti-
bodies and their induction by natural exposure or
immunization are a long-standing subject of funda-
mental and epidemiological studies as well as clinical
vaccine trials [5].
The most commonly studied antigens in this respect
are merozoite antigens, which are expressed both by ma-
ture liver schizonts as well as during the late schizont
and merozoite-stage of blood-stage Plasmodium para-
sites [6]. Studies in different cohorts or transmission
settings sometimes yield contradictory results [6]. One
hypothesis is that a certain threshold of antibody responses
has to be reached for them to be protective [7]. Other im-
portant considerations in immuno-epidemiological studies
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when assessing associations between immunological read-
outs, such as humoral responses and clinical protection,
include the type of follow-up, the time point of assessment
of humoral responses, the definition of ‘protection’ and
the number of time points at which immunological read-
outs are assessed [6]. Additionally, recognition of multiple
antigens in combination rather than just a single antigen
are likely required for protection [8-10], which is already
taken into account in several vaccine development studies
and clinical trials [5].
Using a set of samples collected at four time points from
a cohort of children followed up longitudinally for seven
months, it was investigated whether a high concentration
of antibodies against different pre-erythrocytic, blood-
stage and cross-stage antigens, namely circumsporozoite
antigen (CSP), merozoite surface protein (MSP)-3, apical
membrane protein (AMA)-1, MSP-119 and glutamine-rich
protein (GLURP-R0), alone or in combination, may be
associated with protection from clinical malaria in a
hyper-endemic area. It was further assessed whether this
association was temporally stable or dependent on the
time point of sampling.
Methods
Study area
This study was conducted in Malian children from
Samako, a village of about 3,000 people located in the
Sudanese savannah zone of the Upper Niger valley
(district of Kati) about 70 km southwest of Bamako, the
capital of Mali. Samako is 5 km from Bancoumana
where the Malaria Research and Training Centre has
established a malaria vaccine site since 2000. Plasmodium
falciparum is the predominant Plasmodium species in this
region and accounts for more than 95% of malaria
cases [11]. Transmission is mainly seasonal from June
to December [11]. The study area has previously been
described as a malaria hyper-endemic area [12]. From
July to December of 2011, the overall incidence rate
of clinical malaria during the transmission season pe-
riod was 1.0 (244/243) episodes of malaria per person
per season with 0.56 (28/50), 1.56 (78/50), 1.46 (102/70),
0.48 (35/73) episodes per person per season respectively
in the age categories 3–11 months, 1–4 years, 5–14 years,
and 15–50 years (Kone et al., unpublished data).
Ethical issues
Written informed consent was obtained from parents or
legal guardians who consented on behalf of their
children. All laboratory procedures were carried out
within the guidelines of good laboratory practice.
Ethical clearance to conduct the study was sought from
the ethical committee of the Faculty of Medicine,
Pharmacy and Odonto-Stomatology at the University
of Science, Techniques and Technologies of Bamako
(approval number 2011-58/FMPOS).
Study subjects, design and conduct
One physician and one biologist were based in the village
to follow up a cohort of children aged two to 14 years dur-
ing one malaria transmission season. In December 2011,
171 children were enrolled in the study and subsequently
attended three additional cross-sectional visits during the
transmission season in July 2012 (n = 134) and September
2012 (n = 137) and after the end of the transmission sea-
son in February 2013 (n = 111). Ninety-nine children
attended all three cross-sectional visits and provided sam-
ples during and after the 2012 transmission season and
were selected for longitudinal immunological analysis in
this study.
From July until December clinical malaria infection
was monitored by active and passive case detection. The
active case detection was carried out by house visits and
cross-sectional survey. On a 14-day basis, field workers
conducted active house visits to all the children to assess
malaria infection. Participants were instructed to register
any possible malaria symptoms in a diary. Passive case
detection of clinical malaria episodes was carried out at
the village health clinic. Children who visited the health
clinic were identified using an individual identification
card and were screened by a doctor. When children re-
ported any of the malaria symptoms (fever, headache,
diarrhoea, vomiting), a rapid diagnostic test (OptiMAL,
Flow Inc, Portland, OR, USA) and thick smear were per-
formed and axillary temperature was checked. A clinical
malaria episode was defined by presence of any symp-
tom of malaria including fever of 38°C or more, associ-
ated with a parasitaemia of at least 5,000 trophozoites/
mm3, taking into account that low parasite densities are
not always the causative factor of clinical symptoms
[13]. Children with asymptomatic parasitaemia were not
drug treated, neither at enrolment nor during follow-up.
Out of the 99 children providing plasma samples at all
cross-section visits, 74 developed thick-smear detectable
and 17 developed PCR-detectable infections with P.
falciparum during follow-up (Figure 1). For eight chil-
dren, no parasitaemia was detected at any time point
during follow-up, so they were deemed unexposed.
Children with co-infection of P. falciparum with other
Plasmodium species, such as Plasmodium malariae,
Plasmodium ovale or Plasmodium vivax were excluded
from the analysis in the present study.
Sample collection and sample processing
At each cross-sectional visit, 2–5 ml of blood was col-
lected by venipuncture. About 20 μl of the blood was
used to prepare a thick and thin smear for the detection
of malaria parasites. Slides were stained with Giemsa at
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pH 7.2. A drop of whole blood was placed on Whatman
filter paper strips number 3 (Whatman, Clifton, NJ,
USA) and stored at room temperature for retrospect-
ive PCR analysis to detect sub-microscopic infections.
EDTA anti-coagulated plasma was collected and cryo-
preserved at −20°C.
Indirect enzyme-linked immunosorbent assay (ELISA)
The following antigens were used to assess humoral
responses: (i) the ectodomain of apical membrane anti-
gen (AMA)-1 of P. falciparum FVO, comprising amino
acids 25–545, expressed in the yeast Pichia pastoris
[14,15]; (ii) the conserved non-repeat N-terminal region
R0 of glutamate rich protein (GLURP-R0; amino acids
85–213) [16]; (iii) full-length merozoite surface protein
(MSP)-3 (K1) [17]; (iv) the 19-kilodalton carboxy-terminal
fragment of MSP-1, expressed in Escherichia coli (MSP-
119) [18]; and, (v) full-length circumsporozoite protein
(CSP) obtained from Genova Biotechniques Pvt. Ltd,
Hyderabad, India.
While CSP is a pure pre-erythrocytic antigen expressed
during the sporozoite and liver-stage of the parasite
[19-21], and MSP-3 can only be detected on blood-stage
parasites [22], AMA-1 [23-26], MSP-1 [27-29] and GLURP
[30] are cross-stage antigens expressed during both the
pre-erythrocytic and blood-stage of the parasite.
Microtitre plates (Maxisorb; NUNC) were coated with
50 μl of antigen diluted in PBS at a concentration of 1
μg/ml (AMA-1), 0.5 μg/ml (GLURP-R0), 0.18 μg/ml
(MSP-119), 0.5 μg/ml (MSP-3) or 0.25 μg/ml (CSP).
Plates were incubated overnight at 4°C, washed and
blocked with 200 μl of 5% milk powder in PBS for one
hour. Due to the expected high inter-individual variation
in antibody titers, plasma samples were assayed at two
different dilutions (1:500 and 1:50) to ensure that at least
one of the two would fit into the range of the standard
curve. Fifty μl of diluted plasma samples were added in
duplicate and incubated at room temperature for three
hours. Plates were washed four times between steps.
Polyclonal goat anti-human IgG-HRP (Pierce, Thermo
Scientific) diluted 1:40,000 was added to antigen-coated
plates. Bound secondary antibodies for total IgG were
quantified with ready-to-use TMB (tetramethylbenzidine;
TebuBio Laboratories) substrate for 30 min. Fifty μl of
0.2 M H2SO4 were used to stop the reaction. The plates
were read out at the spectrophotometrical absorbance of
450 nm.
A plasma pool of hyperimmune Tanzanian adults
living in a highly malaria-endemic area was used as
serum standard, defined to contain 100 arbitrary units
(AU) [31]. Optical density values for the test samples
were converted into antibody units with the standard
reference curves generated for each ELISA plate using a
four-parameter, curve-fit, Microsoft Excel-based applica-
tion ADAMSEL-v1.1 [32].
Parasite detection by PCR
DNA was extracted from filter papers using the Chelex
protocol as described by Walsh et al. [33]. The 18S PCR
protocol developed by Snounou et al. [34] targeting the
small ribosomal subunit of P. falciparum was used. PCR
was performed according to the original protocol except
that the quantity of template used in the N1 reaction
was increased from 1 to 5 μl. In every set of PCR condi-
tions 5 μL template was used in the N1 reaction and 1.5
μl of product in the N2 reaction. For a more detailed over-
view of primer sequences and product sizes, and PCR cyc-
ling conditions, see Additional file 1 and Additional file 2,
respectively. Pooled DNA extracts from P. falciparum
NF54 cultured in Nijmegen, The Netherlands were run on
every PCR plate as a positive control, alongside a negative
water control. The positive control was diluted to the
extent that both N1 and N2 fragments were sufficiently
amplified so that both amplicons could be visualized on
agarose gel. N1 and N2 products were mixed and 10 μl
was visualized on 0.8% agarose gel by electrophoresis in
0.5× Tris-acetate-EDTA buffer (0.04 M Tris-acetate and 1
mM EDTA, pH 8.0).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
v5 software and STATA version 12.0 (Statacorp, College
Station, Texas, USA). Differences in responses among
different subject groups (different age groups; asymptom-
atic and symptomatic individuals; low, intermediate and
high responders) were analysed by non-parametric mea-
sures. Mann–Whitney U test was used for two separate
Figure 1 Flow chart of subjects and sample availability for
humoral analysis. Of 170 children aged two to 14 enrolled in this
study, 99 attended all three visits and provided plasma samples;
91 of these experienced parasitaemia (detected by thick smear or
qPCR) during follow-up; 44 of these developed clinical disease once
or more times.
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groups, Kruskal-Wallis with Dunn’s multiple comparison
post-hoc test for more than two groups and Wilcoxon
matched-pairs signed rank test for paired analysis of two
time points. Associations between age and humoral
responses were assessed by Spearman correlation; as-
sociations between the number of antigens recognized
(AU > 10) and age in categories (2–5, 6–9 and 10–15
years), parasite status at enrolment (parasite-free, sub-
microscopic and microscopic parasite carriage) and
‘protection’ (asymptomatic parasite carriage or more
than one clinical malaria episode) was determined by
Poisson regression where the number of antigens recog-
nized was analysed as count variable. Trends in the pro-
portion of individuals recognizing ≥1 or ≥3 antigens and
age in categories or parasite status were determined by
logistic regression. The association between experiencing
clinical malaria episodes or asymptomatic malaria and the
density of antibody responses was further assessed by
logistic regression models with antibody densities as
categorical variables (<1 AU, 1–10 AU and ≥10 AU). For
analyses where ELISA outcomes were analysed on a con-
tinuous scale, AU were log-transformed (log10) and ana-
lysed by linear regression. All associations were adjusted
for age where appropriate. A p-value of < 0.05 was consid-
ered statistically significant.
Results
Association of antibody titres and breadth of the humoral
response with age and parasitaemia
A longitudinal study was performed in 99 children
during one malaria transmission season in Samako, a
village in a hyperendemic area of Mali. The frequency
of P. falciparum infections was highest during the July
cross-sectional visit at the beginning of transmission sea-
son, with a frequency of slide positive children of 27.6%
(27/98), and a proportion of parasite-positive children by
PCR of 78.6% (77/98) (Table 1). Both the demographic
and parasitological parameters of this longitudinal cohort
were highly similar to the original total cohort of 171
children, from which this longitudinal cohort was se-
lected based on attendance of all four cross-sectional
visits (Additional file 3). The number of clinical malaria
episodes recorded during longitudinal follow-up of this
cohort from July to Dec 2012 peaked in October (July
n = 1, Aug n = 8, Sept n = 9, Oct n = 19, Nov n = 17,
Dec n = 4).
Antibody responses against five P. falciparum malaria
antigens were assessed in the cohort at enrolment, the
beginning of the transmission season (baseline), during
and after the transmission season. At all time points
there was a positive correlation between age and anti-
body titres for AMA-1, MSP-3, CSP and GLURP-R0,
while responses to MSP-119 were not associated with
age (Additional file 4). Stratification of children into
three age categories of two to five years, six to nine years
and ten to 15 years revealed that the main increase in
AMA-1 titres occurred before the age of six, while anti-
body levels for MSP-3, CSP and GLURP-R0 rose in a
more continuous manner, which was evident both at
baseline (Figure 2) and at the peak and end of the trans-
mission season (Additional file 5 and Additional file 6).
The next question was whether the breadth of the
response also increased with age. Indeed, at all time
points during follow-up there was a significant correl-
ation between age and the number of antigens to which
children showed an antibody level that reached at least
10% (>10 AU) of the hyperimmune reference serum
(Additional file 4). Stratification into age groups showed
that this increase occurred again before the age of
six, with no difference between the older age groups
(Figure 3A). Early in the transmission season (July 2012)
47.2% (17/36) of the children in the youngest age group
had no high reactivity to any of the antigens, which de-
creased to 29.6% (8/27) in six to nine years old and 16.7%
(6/36) in ten to 14 years old (p for trend = 0.007). While
only 13.9% (5/36) of the two to five years old had high
levels of antibodies against three or more antigens, this
proportion was more than twice as high in six to nine year
Table 1 Demographic and parasitological parameters
Dec 2011 Jul 2012 Sept 2012 Feb 2013
Number of individuals (N) n = 99
Gender,% male (n/total) 55.6% (55/99)
Age in year, median (range) 7 (2–14)
Haemoglobin (g/dL), median (range) 11.6 (7.3-14.5) 11 (7.4-14.3) 11.6 (6.5-14.6) 12.2 (5.7-16.3)
Anaemia,% Hb <11 g/dL (n/total) 26.3% (26/99) 47.5% (47/99) 27.3% (27/99) 13.3% (13/98)a
Thick smear positive (%, n/total) 18.2% (18/99) 27.6% (27/98)a 20.2% (20/99) 10.8% (10/93)a
PCR positive (%, n/total) n.d. 78.6% (77/98)a 43.6% (41/94)a n.d.
Parasitaemia in thick-smear positive
individuals (n = 35), median (range)
12,900 (100–51,300) 3,150 (100–132,275) 1,262 (100–58,675) 1,325 (100–7775)
n.d. not done.
aFor some children not all data were collected at the time of visit.
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old children (29.6%, 8/27) and ten to 14 years old children
(30.6%, 11/36); Figure 3B) (p for trend = 0.10). The
breadth of the humoral response was significantly associ-
ated with parasitaemia at time of sampling (Figure 3C):
57.1% (12/21) of children with no detectable parasites rec-
ognized not a single antigen strongly, while this was only
true for 28.0 (14/50) and 14.8% (4/27) of children with
sub-microscopic or microscopic parasitaemia, respectively
(p for trend = 0.007), after adjustment for age. While there
was no significant difference in microscopically detec-
table parasitaemia between the different age categories
(p = 0.79), PCR detectable parasitaemia, regardless of
thick smear positivity, however, increased with age (p =
0.04; Figure 3D).
Dependency of boosting of humoral responses on early
season antibody levels
The breadth of the antibody response, i.e., the number of
antigens strongly recognized (>10 AU) per individual, was
stable over the time of follow-up, as evidenced by the
strong correlation between this readout at enrolment
(December 2011) and the beginning (July 2012; Spearman
Figure 2 Humoral responses by age at the beginning of the transmission season. Antibody reactivity against P. falciparum antigens was
assessed in samples from (n = 99) children collected at baseline. A pool of sera from 100 hyperimmune Tanzanians (HIT) was used as a standard
positive control. Reactivity for each antigen in undiluted HIT serum was set at 100 arbitrary units (AU). Humoral reactivity was assessed against
(A) AMA-1, (B) MSP-119, (C) MSP-3, (D) CSP and (E) GLURP-R0. Children were divided into three different age groups: two to five years (n = 36),
six to nine years (n = 27) and ten to 14 years (n = 36). Responses between the three age groups were compared using Kruskal-Wallis with Dunn’s
multiple comparison post-test. *p < 0.05; **p < 0.01; ***p < 0.001. Scatter plots show individual data points, horizontal lines indicate the median
of the group and error bars the interquartile range (IQR).
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r = 0.59, p < 0.0001), peak (September 2012; r = 0.70, p <
0.0001) and end of the transmission season (February
2013; r = 0.67, p < 0.0001). Next it was investigated
whether exposure during the transmission season al-
tered antibody levels for the individual antigens. During
the seven months of follow-up, 91/99 children became
parasite-positive by either PCR or thick smear during
one or more visits. Of these, 47 children remain asymp-
tomatic while 44 experienced one or more episodes of
clinical malaria (Figure 1).
Comparing antibody responses in all n = 91 malaria
exposed children, there were no statistically significant
difference for any of the antigens were observed between
the beginning and end of the transmission season,
(median AU [July 2012, February 2013]: AMA-1 [7.8,
7.2] p = 0.058; MSP-119 [2.37, 2.51] p = 0.46; MSP-3
[11.6, 12.0] p = 0.27; CSP [6.14, 4.66] p = 0.18; GLURP-
R0 [3.40, 3.09] p = 0.80). Since boosting of antibody re-
sponses may depend on the strength of the pre-existing
response, all exposed children (n = 75) were stratified
into low (<1 AU), intermediate (1–10 AU) and high
responders (>10 AU) for each antigen. Low early season-
responders for AMA-1, MSP-119 and GLURP-R0 showed
higher antibody levels after the transmission season, while
these titers remained largely unchanged in intermediate
early season-responders (Table 2). For MSP-3, there was
only a single low early season-responder. For this antigen,
intermediate early season-responders showed boosted
antibody levels after the transmission season. The oppos-
ite was observed for children showing high early season
antibody responses: for these children, post-transmission
season antibody levels for MSP-119, MSP-3 and CSP were
significantly lower than their titers at the beginning of
the season (Table 2). In contrast, boosting or waning of
antibody titers was not depend on age, since without
stratification by early season antibody titers, there was
no significant difference between early and post-season
antibody titers in any of the different age categories
(Additional file 7).
Preferential boosting in the group of children with low
antibodies at the beginning of the season could be due
to the particularly high frequency of clinical malaria
Figure 3 Relationship of multiple antigen recognition with age and parasitaemia early in the transmission season. The humoral
response was analysed according to the number of antigens strongly recognized by each individual (n = 99) at the beginning of transmission
season (July 2012). An arbitrary cut-off of 10 AU was used for each antigen and subjects were stratified by age. The three age groups: two to five
years (n = 36), six to nine years (n = 27) and ten to 14 years (n = 36) were compared using Kruskal-Wallis with Dunn’s multiple comparison
post-test. *p < 0.05; **p < 0.01; ***p < 0.001. (A) Scatter plots show individual data points, horizontal lines indicate the median of the group.
(B) For each age group, the percentage of children strongly recognizing 0 or more antigens at baseline is shown and was analysed as count data by
Poisson regression (overall association between age group and number of antigens recognized: p = 0.001). (C) Parasitaemia was assessed at the
beginning of the transmission season (July 2012) by thick smear (TS) and PCR in 98 children (one TS negative child was excluded from analysis since
no filter paper was available for PCR analysis). The proportion of children recognizing different numbers of antigens strongly (>10 AU) was stratified
based on parasitaemia at time of sampling - not detectable (TS-PCR-; n = 21), sub-microscopic (TS-PCR+; n = 50) or microscopic (TS + PCR+; n = 27)
and analysed as count data by Poisson regression (overall association between parasite status and the number of antigens recognized, p = 0.002).
(D) The proportion of children with either no detectable (TS-PCR-; white), sub-microscopic (TS-PCR+; grey) or microscopic parasitaemia (TS + PCR+; black)
in the three different age categories was analysed by logistical regression for the different diagnostics separately (p = 0.47 for TS+, p = 0.042 for
total PCR+).
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episodes during the transmission season in this group,
compared to the intermediate or high early season-
responders. This was indeed observed regardless of
which antigen was used for stratification (Additional file 8).
One possible explanation for lower antibody levels after
the transmission season compared to baseline, as found in
the high early season-responder group, might be tem-
porarily elevated antibody levels at baseline due to an
ongoing malaria infection. Indeed, there was a trend
that the frequency of children with microscopic parasit-
aemia was highest in the early season high responder
group and lowest in the early season low responder
group for GLURP (p = 0.02), AMA-1 (p = 0.06) and MSP-
1 (p = 0.11) (Additional file 9). For AMA-1 (p = 0.04) and
MSP-3 (p = 0.03), this distinction was even found for
the total proportion of children with any (either sub-
microscopic or microscopic) parasitaemia, despite the fact
that the majority of children (77/90) included in this lon-
gitudinal analysis was PCR positive at baseline.
Association of antibody responses with clinical protection
Because the youngest children showed overall weaker
antibody responses and recognized a smaller number of
antigens strongly than older children, it was next verified
whether age might be a determinant for protection from
clinical malaria during the transmission season. Overall,
children remaining asymptomatic were older than those
experiencing clinical malaria episodes, although this
difference was not statistically significant (Figure 4A;
p = 0.09). When age was dichotomized, children two
to five years of age had a higher proportion of clinical
episodes than the two older age groups (p = 0.049;
Figure 4B). Therefore, all the following statistical ana-
lyses were adjusted for age.
Compared to children developing clinical malaria epi-
sodes, asymptomatic children showed significantly higher
levels of antibodies against AMA-1, and non-significantly
higher antibody responses for MSP-3 and GLURP-R0, at
the start of the season (Figures 5A, C and E). These differ-
ences in antibody levels found early in the transmission
season were also observed at enrolment and during lon-
gitudinal follow-up for AMA-1, MSP-3 and GLURP-R0
(Additional file 10A, C and E; Additional file 11A and C;
Additional file 12A and E). However, none of these differ-
ences were statistically significant when adjusted for age.
The levels of anti-MSP-119 and anti-CSP antibodies were
comparable between children remaining asymptomatic
and symptomatic at enrollment (Additional file 10) and
during the entire follow-up (Additional files 11B and 12B).
When antibody responses were dichotomized as high
responders (>10 AU) and low responders, only high anti-
body responses to AMA-1 (AU > 10) in July 2012 were
associated with a lower risk of clinical malaria epi-
sodes in the subsequent season (OR 0.37, 95% CI 0.15-
0.91, p = 0.03). No such association was observed MSP-1
(OR 0.92, 95% CI 0.35-2.37, p = 0.86), MSP-3 (OR 0.60,
95% CI 0.25-1.40, p = 0.24), GLURP (OR 0.62, 95% CI
0.21-1.80, p = 0.38) or CSP (OR 1.00, 95% CI 0.39-
2.57, p = 0.99).
While recognition of individual antigen was therefore
no good predictor of protection from clinical disease,
children remaining asymptomatic recognized a broader
repertoire of antigens compared to those that developed
clinical disease (Figure 6A (December 2011, p = 0.03); B
(July 2012, p = 0.12); C (February 2013, p = 0.008)). Al-
though not always statistically significant, across all time
points analysed, a greater proportion of children that be-
came symptomatic during the season lacked high reactivity
Table 2 Changes of antibody titers after parasite exposure during the transmission season dependent on baseline
reactivity
AMA-1 MSP-119 MSP-3 CSP GLURP-R0
<1 AU n = 21a n = 28 n = 1 n = 6 n = 15
July 2012 median [IQR] 0.094 [0.01-0.25] 0.22 [0.01-0.6] 0.73 [0.50-0.86] 0.48 [0.2-0.62]
Feb 2013 median [IQR] 0.34 [0.09-2.0] 0.95 [0.05-2.0] 1.99 [1.39-2.24] 1.30 [0.88-2.16]
p-valueb 0.002 <0.0001 n.d. 0.03 0.002
1-10 AU n = 28 n = 39 n = 43 n =59 n = 56
July 2012 median [IQR] 3.0 [1.62-6.89] 2.5 [1.35-4.72] 5.05 [3.75-7.23] 4.16 [1.88-6.98] 3.15 [2.12-4.90]
Feb 2013 median [IQR] 4.4 [1.91-10.05] 2.46 [1.08-4.21] 7.21 [4.87-12.73] 4.66 [2.19-8.12] 3.06 [2.08-6.05]
p-valueb 0.067 0.96 <0.0001 0.11 0.33
>10 AU n = 42 n = 24 n = 47 n = 26 n = 20
July 2012 median [IQR] 37.1 [15.1-75.7] 23.9 [16.1-68.9] 29.8 [16.1-82.2] 14.7 [11.7-22.4] 22.4 [13.3-57.6]
Feb 2013 median [IQR] 36.1 [11.1-108.8] 15.3 [6.9-46.2] 19.9 [9.7-51.2] 8.1 [3.96-14.1] 20.2 [3.5-89.9]
p-valueb 0.45 0.047 0.002 <0.0001 0.59
a91 children that experiences parasitaemia detected by qPCR or thick smear where included in this analysis.
bAntibody reactivity was compared between July and February for each group and antigen by Wilcoxon matched-pairs signed rank test.
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to any of the antigens compared to asymptomatic children,
while strong responses to three or more antigens were
found in a greater proportion of asymptomatic children
compared to those that were clinically unprotected
(Figure 6). Amongst those children with high reactivity
for three to five antigens, 95.4% had strong responses
for MSP-3 (median across all time points), 81.0% for
AMA-1, 72.3% for CSP, 66.3% for GLURP-R0 and 53.8%
for MSP-119. Children strongly recognizing three or
more antigens has a reduced risk of developing clinical
malaria, both when antibody titers were assessed prior
to (prospective analysis, December 2011 and July 2012)
or after (retrospective analysis, February 2013) the 2012
transmission season, in which clinical malaria was
detected (Figure 6D). Again, these data did not all reach
significance, but showed a clear trend across time
points.
Discussion
Immuno-epidemiological studies in multiple settings are
needed to further an understanding of the relationship
between naturally acquired antibody responses to the
parasite and protection from clinical malaria. The key
finding of the present study is that in a highly endemic
area in Mali, the risk of developing clinical malaria upon
exposure was reduced when children showed strong
recognition of three or more malaria antigens at any
time point during the study, regardless whether those
responses were measured before or after the malaria risk
was assessed.
Studies into antibody correlates of protection can be
affected by a number of confounders. A meta-analysis of
other studies assessing the association between anti-
bodies and protection from clinical disease found that
most studies do not exclude individuals without detected
parasitaemia during follow-up from the ‘protected’
group, although there is no evidence that these individ-
uals were even exposed [6]. Such practice may decrease
the magnitude of the observed effect between high and
low responders [35]. In the present study, individuals
without evidence of malaria exposure during the study,
as assessed by PCR and microscopy, were excluded from
the analysis on clinical protection. In this context, a limi-
tation of any immune-epidemiological study including
the present one, in assessing exposure to the parasite is
the frequency of monitoring for parasitaemia. Ideally,
parasitaemia would be determined at weekly intervals
by PCR. In the present study, parasitaemia was only
assessed microscopically at the four cross-sectional
visits, or when children reported malaria symptoms
during the bi-weekly active case detection visits or at
the local health clinic. Furthermore, PCR data were
only available for two of the cross-sectional visits.
This sampling approach detected many asymptomatic
infections that allowed us to exclude potentially unex-
posed individuals [35], but may not have captured all
infections and therefore may have resulted in the ex-
clusion of some individuals with asymptomatic infec-
tions of short duration [36]. Of note, in the present
study setting, a considerable proportion of infections
were detectable by PCR only [37,38]. Parasite prevalence
was almost threefold higher by PCR than by microscopy,
which has been reported before but is higher than
typically observed in areas with this level of transmis-
sion intensity [37]. The findings suggest that a consider-
able proportion of children are capable of controlling
infections to densities below the microscopic threshold
density for detection.
Figure 4 Relationship between age and clinical protection. (A) The age of all children who developed parasitaemia by PCR or thick smear
during follow-up (total n = 91) in the asymptomatic (n = 47) and symptomatic groups (n = 44) is plotted. Scatter plots show individual data
points, horizontal lines indicate the median of the group and error bars the interquartile range (IQR). The two groups were compared using
Mann–Whitney U test. (B) The proportion of children experiencing 0, 1, 2 or 3 clinical episodes was calculated for the three different age groups
(two to five years, six to nine years and ten to 14 years) and analysed as count data by Poisson analysis.
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Age, reflecting cumulative malaria exposure, is an im-
portant determinant of protection against clinical mal-
aria. In this study, children ranging from age two to 14
years were enrolled. A decreasing risk for clinical mal-
aria [39], severe disease [40], and an increase of antibody
responses [41,42] with age are commonly reported. Ac-
cordingly, in the present study, an increase in humoral
responses and clinical protection particularly up to the
age of six years was also observed. As a result, appar-
ently stronger antibody responses to AMA-1, MSP-3
and GLURP-R0 at the beginning of the transmission
season in children protected from clinical disease were
found to be largely explained by their higher age. Never-
theless, even when adjusting for age, high responders to
AMA-1 and high responders to a combination of three
or more antigens had a lower risk for clinical disease.
Therefore, it is no age per se, but the acquisition of spe-
cific and strong responses with the degree of cumulative
exposure that determines humoral protection.
An important consideration when interpreting the
findings from the current study is the size of the study
cohort. In the current study, the number of children
from which samples could be analysed was reduced by a
number of factors, including commitment to longitu-
dinal assessment and attendance of all cross-sectional
visits. This approach was chosen to allow for a single
consistent data set to be used for all analysis, as opposed
to doing analysis for each time point with a different,
only partially overlapping set of participants. While
this did not lead to a skewing in the demographic or
Figure 5 Relation between antibodies at the beginning and clinical protection during the transmission season. Humoral responses at the
beginning of the transmission season were assessed by ELISA against (A) AMA-1, (B) MSP-119, (C) MSP-3, (D) CSP and (E) GLURP-R0. The n = 91
children who developed parasitaemia by PCR or thick smear during follow-up were divided into two groups: a group consisting of asymptomatic
children who experienced no clinical episode of malaria during the transmission season (n = 47), and a group of children who had a symptomatic
malaria episode at least once during the transmission season (n = 44). Differences between the two groups were analysed by linear regression of
log-transformed (log10) data, adjusting values for age. Age adjusted P values are shown for each plot, with p-values without age adjustment
(Mann–Whitney U test) in brackets. Scatter plots show individual data points, horizontal lines indicate the median of the group and error bars the
interquartile range (IQR).
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Figure 6 Relationship between strong humoral responses to multiple antigens and risk of clinical malaria. Children who developed
parasitaemia by PCR or thick smear during follow-up (n = 91) were divided into asymptomatic children who experienced no clinical episode of
malaria during the transmission season (n = 47), and children who had a symptomatic malaria episode at least once during the transmission season
(n = 44). For both groups, the percentage of children strongly recognizing 0 or more antigens is shown at (A) enrollment, (B) in the beginning and
(C) after the transmission season. An arbitrary cut-off of 10 AU was used for each antigen. Horizontal bars indicate the percentage of children in each
group recognizing three or more antigens strongly. The number of antigens to which high reactivity (>10 AU) was observed was analysed as count
data by Poisson regression. (D) The risk of developing clinical malaria during the transmission season was calculated by logistic regression analysis for
children that were high responders (>10A AU) for 1, 2, 3, 4 or 5 antigens simultaneously in reference to those that recognized not a single antigen
strongly, with adjustment for age. Analysis was performed either prospectively (using December 2011 or July 2012, i.e. before clinical episodes were
recorded, excluding one volunteer that experienced a clinical episode in July from the analysis), or retrospectively (using post-season February 2013
antibody titers). Symbols depict odds ratios, error bars indicate the upper and lower 95% confidence interval.
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parasitological parameters compared to the original
cohort, the two groups of children remaining asymptom-
atic or becoming symptomatic upon parasite exposure
were too small for several of the results to reach statistical
significance. Nevertheless, clear trends were observed
throughout time points, justifying future studies in larger
cohorts.
It was previously highlighted that studies measuring
responses at multiple time points are needed to better
determine the serological status of an individual and
whether the time point of observation may have an im-
pact on the association of the humoral responses with
protection [6,43]. Changes in antibody titres after expos-
ure were, therefore, also examined. Overall, breadth and
magnitude of the antibody response in this cohort were
stable over the period of observation that comprised one
complete transmission season. This stability of antibody
responses may explain why associations of clinical pro-
tection with recognition of multiple antigens could be
observed at any time point examined. This may, how-
ever be different in other transmission settings, where
antibody levels are less stable. With the exception of
AMA-1, boosting of antibody titres during the transmis-
sion season could only be observed when children were
stratified by their baseline antibody levels, rather than
when analysed as a whole group or stratified by age.
Children with low baseline antibodies level showed
boosting of blood- and cross-stage antigens and a similar
trend for the pre-erythrocytic antigen CSP. Surprisingly,
children with high baseline antibodies level (>10 AU)
showed decreased rather than increased titres after the
transmission season, which coincided with a lower fre-
quency of clinical malaria episodes that these children
experienced during the transmission season. The risk of
symptomatic malaria and disease severity is often associ-
ated with higher parasitaemia [39,44]. Whether the lower
frequency of clinical malaria episodes in this group also
reflects lower parasitaemia and hence less antigen expos-
ure during asymptomatic episodes in the transmission
season could not be determined, since parasitaemia mea-
surements were available from too few time points. Lower
antigen exposure would, however, at least partially explain
the less efficient boosting of antibody responses in this
group of children.
The apparent decrease in antibody titres over the trans-
mission season in these children might be an artifact
caused by asymptomatic parasitaemia at time of plasma
sampling: At the beginning of the transmission season the
group of children with the highest antibody titres for indi-
vidual antigens also had the highest frequency of parasit-
aemia, detected either by thick smear or PCR.
That concurrent, even asymptomatic, low-density para-
sitaemia is associated with elevated antibody titres or
prevalence, is in line with previous data [35,41,45-48].
Similarly, the number of strongly recognized antigens was
also higher when children carried parasites at the time of
sampling, again in line with other studies [10]. Such
elevated antibody levels during or shortly after acute in-
fection mostly stem from short-lived plasma blasts, only
some of which will eventually establish themselves in
survival niches as long-lived plasma cells [49]. Contraction
of this short-lived response soon after parasite clearance
results in a drop of antibody levels that is well reported
for malaria antigens [47,50] and might be relatively greater
than the small increase in stable antibody levels (in the
absence of parasites or exposure) derived from long-lived
plasma cells induced during the transmission season [42].
Amongst the four blood- and cross-stage antigens ex-
amined, MSP-119 was the only one for which reactivity
did not increase with age, nor did titers for it differ at all
clinical protection in this study. Although antibodies to
MSP-119 are generally found to confer protection [6,51],
this effect is weakest for the Wellcome allele of MSP-119
[6] and also was not found by all studies [52], the reason
for which could be the exact source and sequence of
antigen, but also actual difference between cohorts. The
result of the present study is in line with a previous
study finding no protection-association when using the
same MSP-119 antigen [10]. Antibody titers for the other
blood- and cross-stage antigens AMA-1, MSP-3 and
GLURP showed either no significant difference or only
trends for slightly higher responses in children remaining
asymptomatic; any apparent differences here were clearly
age-confounded. Further, there was no difference in CSP
antibody titers between children protected or not from
clinical disease. Although occasionally reported [53], CSP
responses are not commonly found to be associated with
clinical protection [54-57], but can rather confer protec-
tion from infection at high titres [58].
When analysed as single antigens, only antibody re-
sponses to AMA-1 were found to be associated with a
reduced risk of clinical malaria. In contrast, high respon-
ses for a combination of at least 3/5 malaria antigens
showed a relatively consistent protective effect across all
time points analysed. These findings are in line with previ-
ous studies showing that protection against malaria may
not be associated with the humoral responses to one anti-
gen in isolation, but instead with recognition of a panel of
antigens [8-10,59,60]. Moreover, MSP-3 and AMA-1 were
more prevalently recognized than other antigens amongst
children showing responses to multiple antigens, confirm-
ing a previous study showing that recognition of these two
antigens in combination was more strongly associated
with protection than other combinations [10]. In the
present study, assessment of antibody responses was
limited to five classical vaccine candidate antigens by
conventional ELISA. Recently, it was reported that
Kenyan children have antibody responses against novel
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and little-studied merozoites proteins, which had high
protective efficacy, particularly when five out of the ten
leading proteins were recognized [59]. Application of
protein microarrays probed with a large set of P. falcip-
arum antigens to samples from the present and similar
studies with carefully defined, protected and non-
protected cohorts will be a useful tool to extend these
findings and add to the first few existing studies to iden-
tify novel antigens and panels thereof associated with
protection from clinical disease [9,54]. Based on this,
screening for a panel of antigens in field studies could
be implemented using bead-based multiplex ELISAs
[61-63], which are more cost-efficient than full protein
microarrays.
Conclusions
The present study provides immune-epidemiological
evidence from a limited cohort of Malian children that
protection from clinical malaria is associated with high
antibody titres for three or more malaria antigens. Fu-
ture studies should confirm these findings for other set-
tings and study periods with study populations that are
adequately powered to detect more subtle associations
between antibody recognition, age and clinical malaria.
Additional files
Additional file 1: Primer sequences and product sizes. Provides
details of primers used to detect Plasmodium falciparum DNA extracted
from filter papers by PCR.
Additional file 2: PCR Mastermix composition and PCR thermal
cycler programme. Provides details of methodology and PCR cycling
conditions used to detect Plasmodium falciparum DNA extracted from
filter papers by PCR.
Additional file 3: Demographic and parasitological parameters of
total cohort. Provides demographic and parasitological data for all
individuals that attended one or more of the four cross-sectional visits,
out of which the longitudinal cohort of n = 99 children attending all
visits was selected for immunological analysis.
Additional file 4: Correlation between age and humoral responses
during follow-up. Spearman correlation analysis was performed to
analyse for all n = 99 children the relationship between age and the
height of antibody titers to the five malaria antigens AMA-1, MSP-119,
MSP-3, CSP and GLURP-R0 at each of the four visits.
Additional file 5: Humoral responses by age in the middle of the
transmission season. Antibody reactivity against P. falciparum antigens
was tested by ELISA on samples from (n = 99) children collected in the
middle of transmission (September 2012). A pool of sera from 100
hyperimmune Tanzanians (HIT) was used as a standard positive control.
Reactivity for each antigen in undiluted HIT serum was set at 100
arbitrary units (AU). Humoral reactivity was assessed against (A) AMA-1,
(B) MSP-119, (C) MSP-3, (D) CSP and (E) GLURP-R0. Responses between
the three age groups were compared using Kruskal-Wallis with Dunn’s
multiple comparison post-test. *p < 0.05; **p < 0.01; ***p < 0.001.
Scatter plots show individual data points, horizontal lines indicate the
median of the group and error bars the interquartile range (IQR).
Additional file 6: Humoral responses by age after the transmission
season. Antibody reactivity against P. falciparum antigens was tested by
ELISA on samples from (n = 99) children collected after the transmission
(February 2013). A pool of sera from 100 hyperimmune Tanzanians (HIT)
was used as a standard positive control. Reactivity for each antigen in
undiluted HIT serum was set at 100 arbitrary units (AU). Humoral
reactivity was assessed against (A) AMA-1, (B) MSP-119, (C) MSP-3, (D) CSP
and (E) GLURP-R0. Responses between the three age groups were
compared using Kruskal-Wallis with Dunn’s multiple comparison post-test.
*p < 0.05; **p < 0.01; ***p < 0.001. Scatter plots show individual data points,
horizontal lines indicate the median of the group and error bars the
interquartile range (IQR).
Additional file 7: Changes of antibody titers after parasite exposure
during the transmission season dependent on age. All n = 91
children that were exposed to the malaria parasite during follow-up were
divided into age categories of two to five years (n = 35), six to nine years
(n = 27) and ten to 14 years (n = 36). Antibody titers early during (July
2012) and after the transmission season (February 2013) were compared
by Wilcoxon matched-pairs signed rank test.
Additional file 8: Frequency of clinical malaria episodes in children
stratified based on their reactivity to different Plasmodium
falciparum antigens. All n = 91 children that were exposed to the
malaria parasite during follow-up were stratified based on their antibody
responses to individual malaria antigens in July 2012 (early in the
transmission season) as follows: <1 AU, i.e., <1% of reference HIT serum;
1–10 AU; >10 AU, i.e., >10% of reference HIT serum. Additionally children
were also stratified based on the number of antigens strongly recognized
at this time point, using an arbitrary cut-off of 10 AU (0 antigens, 1–2
antigens and 3–5 antigens). The proportion of children developing
clinical malaria in each group during follow-up is shown.
Additional file 9: Degree of parasitaemia in groups with different
humoral reactivity. For each antigen, children were stratified into three
groups depending on their response to this respective antigen early
in the transmission season (July 2012) as follows: <1 AU, i.e., <1% of
reference HIT serum; 1–10 AU; >10 AU, i.e., >10% of reference HIT serum.
For A) AMA-1, (B) MSP-119, (C) MSP-3, (D) CSP and (E) GLURP-R0, the
proportion of children with no detectable parasitaemia (TS-PCR-),
sub-microscopic (TS-PCR+) or microscopic (TS + PCR+) parasitaemia in
each responder group is shown. Data were analysed by logistic
regression and is shown for TS+ and all PCR+ individuals; values were
adjusted for age.
Additional file 10: Comparison of antibody titers between
asymptomatic and symptomatic individuals in the end of the
previous transmission season. Humoral responses in the end of the
previous transmission season (December 2011) were assessed by ELISA
against (A) AMA-1, (B) MSP-119, (C) MSP-3, (D) CSP and (E) GLURP-R0 for
exposed children remaining asymptomatic (n = 47) or becoming
symptomatic (n = 44) during the season. Reactivity for each antigen in
undiluted hyperimmune Tanzanians (HIT) serum was set at 100 arbitrary
units (AU). Differences between the two groups were analysed by linear
regression of log-transformed (log10) data, adjusting values for age. Age
adjusted P values are shown for each plot, with p-values without age
adjustment (Mann–Whitney U test) in brackets. Scatter plots show
individual data points, horizontal lines indicate the median of the group
and error bars the interquartile range (IQR).
Additional file 11: Comparison of antibody titers between
asymptomatic and symptomatic individuals in the middle of the
transmission season. Humoral responses in the middle of the
transmission season (September 2012) were assessed by ELISA against (A)
AMA-1, (B) MSP-119, (C) MSP-3, (D) CSP and (E) GLURP-R0 for exposed children
remaining asymptomatic (n = 47) or becoming symptomatic (n = 44) during
the season. Reactivity for each antigen in undiluted hyperimmune Tanzanians
(HIT) serum was set at 100 arbitrary units (AU). Differences between the two
groups were analysed by linear regression of log-transformed (log10) data,
adjusting values for age. Age adjusted P values are shown for each plot, with
p-values without age adjustment (Mann–Whitney U test) in brackets. Scatter
plots show individual data points, horizontal lines indicate the median of
the group and error bars the interquartile range (IQR).
Additional file 12: Comparison of antibody titers between
asymptomatic and symptomatic individuals after the transmission
season. Humoral responses were determined by ELISA after the end of
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transmission season (February 2013) in children who either did not
experience any clinical episode of malaria during the transmission season
(asymptomatic; n = 47), or had a symptomatic malaria episode at least
once during the transmission season (symptomatic; n = 44). Antibody
responses were determined for (A) AMA-1, (B) MSP-1, (C) MSP-3, (D) CSP
and (E) GLURP-R0. Reactivity for each antigen in undiluted hyperimmune
Tanzanians (HIT) serum was set at 100 arbitrary units (AU). Differences
between the two groups were analysed by linear regression of
log-transformed (log10) data, adjusting values for age. Age adjusted
P values are shown for each plot, with p-values without age adjustment
(Mann–Whitney U test) in brackets. Scatter plots show individual data
points, horizontal lines indicate the median of the group and error bars
the interquartile range (IQR).
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